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Creutzfeldt-Jakob disease (CJD), a rare
neurodegenerative disorder, affects 0.5 to 1 per-
sons per million population worldwide each year
(1-8). CJD is a human spongiform encephalopathy;
others are kuru, which is associated with ritua-
listic cannibalism in the Fore tribe of Papua New
Guinea; Gerstmann-Sträussler-Scheinker syn-
drome, an inherited disorder; and fatal familial
insomnia, inherited as an autosomal-dominant
trait. Animal spongiform encephalopathies include
scrapie, bovine spongiform encephalopathy (BSE),
transmissible mink encephalopathy, and wasting
disease of elk most frequently referred to as
transmissible spongiform encephalopathies; other
names such as prion dementias, transmissible
degenerative encephalopathies, and infectious
cerebral amyloidoses are also used.
The classic clinical symptoms of CJD are
rapidly progressive presenile dementia, myoclonus,
and progressive motor dysfunction. No treatment
is available, and survival averages less than 1
year (most often 2 to 6 months) (9). Diagnosis is
based on symptoms, electroencephalograms, and
neuropathologic tests (10,11).
The pathophysiology of CJD is incompletely
understood, although it is known that in persons
with the disease, the normal soluble prion
protein (PrPC) is conformationally shifted into a
more stable, less soluble ß-pleated protein. The
term PrPCJD indicates the abnormal isoform found,
with a variety of distribution patterns in the
brain of persons with CJD. Limited proteolysis of
PrPCJD by Western blot analysis shows four pat-
terns of protease-resistant prion protein (12,13).
No screening assay is available to detect PrP
in asymptomatic persons. Cerebrospinal fluid pro-
tein markers can distinguish CJD from other
neurodegenerative disorders in certain settings
(14,15). However, they are not CJD-specific and
are not markers of PrP. The etiologic agent is
believed to be a prion (proteinaceous infectious
particle), although viral etiologies have been pro-
posed (16-18). Sporadic CJD may also result from
the spontaneous conversion of PrPC into PrPCJD or
from somatic mutation in the prion protein gene.
Three epidemiologic forms of CJD are well
recognized: sporadic (the most common), familial,
and infectious/iatrogenic. The familial form (5%
to 10% of cases) results from mutations in the
coding sequence of the PrP gene located on chro-
mosome 20. Polymorphisms at codon 129 have
been correlated with genetic susceptibility to
human prion diseases (19). Fewer than 1% of
human cases of CJD are iatrogenic (20). A new
variant (nv-CJD), which occurred temporally in
association with BSE in cattle in the United
Kingdom, was recently reported (21); a direct
association with food consumption remains
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uncertain. Possible transmission of CJD through
receipt of blood or blood products is a concern.
Routes of iatrogenic transmission are summa-
rized below, followed by a discussion of possible
bloodborne transmission.
Iatrogenic CJD
Although first described in the 1920s, CJD
was not considered a transmissible disease until
1966 when kuru was shown to be transmissible
(22). In 1968, CJD was confirmed to be a trans-
missible spongiform encephalopathy when it was
shown to be transmitted to chimpanzees (23).
Virtually every case of CJD attributed to infec-
tion is iatrogenic; transmission between humans
has been clearly demonstrated during neuro-
surgical procedures with contaminated instru-
ments and through central nervous system tissue
and extract transfer. Worldwide, more than 100
cases of transmissible CJD have been detected,
and new cases continue to appear (Table 1; 27).
The first report of suspected iatrogenic CJD
was published in 1974 (24). Animal experiments
showed that corneas of infected animals could
transmit CJD, and the causative agent spreads
along visual pathways (25,26). A second case of
CJD associated with a corneal transplant was
reported without details (27). In 1977, CJD trans-
mission caused by silver electrodes previously
used in the brain of a person with CJD was first
reported (28). Transmission occurred despite
decontamination of the electrodes (later shown to
transmit disease to experimental primates [29])
with ethanol and formaldehyde. Retrospective
studies identified four other cases likely of simi-
lar cause (30-32). The rate of transmission from a
single contaminated instrument is unknown,
although it is not 100% (31). In
some cases the exposure occur-
red weeks after the instruments
were used on a person with CJD.
CJD was first reported in a
recipient of a dura mater trans-
plant in 1987 (33); a second
case was identified in 1989 in a
25-year-old man from New Zea-
land, who also received dura
mater (34). Because the same
company produced dura mater
for both patients, the dura
mater was suspected as the
source of iatrogenic CJD.
Approximately 15 case reports
have been published, providing information on
20 cases associated with dura mater transplant;
a recent review article indicates that 25 such
cases have occurred throughout the world
(Australia, Canada, Germany, Italy, Japan, New
Zealand, Spain, the United Kingdom, and the
United States) (27). However, Japan has very
recently reported more than 40 cases of CJD in
dura mater recipients (J. Tateishi, Pers. Comm.).
Most dura mater cases have been associated with
a single manufacturer whose manufacturing
processes were inadequate to inactivate the prion
agent. This, combined with pooling of the dura
mater has led to the relatively large number of
cases. The earliest reported transmission occur-
red in a patient who received a dura mater
transplant in 1969 (35). Although recom-
mendations to reduce the risk were made in 1987,
cases have continued to appear because of the
long incubation period. Notably, one of the
most important epidemiologic characteristics
of dura mater transmissions is the young age of
the first reported cases.
By 1985, a series of case reports in the United
States showed that when injected, cadaver-
extracted pituitary human growth hormone
could transmit CJD to humans (36). Shortly
thereafter, it was recognized that human gona-
dotropin administered by injection could also
transmit CJD from person to person (37).
Strain typing based on molecular PrP ana-
lysis and a polymorphism (methionine/methio-
nine, valine/valine or methionine/valine) found
at codon 129 of the PrP gene has been proposed as
a tool for distinguishing between iatrogenic and
sporadic CJD (12,13). Homozygosity at this site
may predispose a person to acquired forms of
Table 1. Transmissible cases of Creutzfeldt-Jakob Disease
Mode of infection No. Agent entry  Mean incubation
of patients into brain period (range)
INSTRUMENTATION
Neurosurgery   4 Intracerebral 20 months (15-28)
Stereotactic EEG   2 Intracerebral 18 months (16-20)
TISSURE TRANSFER
Corneal transplant   2 Optic nerve 17 months (16,18)
Dura mater implant 25 Cerebral surface 5.5 years  (1.5-12))
TISSURE EXTRACT
   TRANSFER
Growth hormone 76 Hematogenous 12 years (5-30)
Gonadotrophin   4 Hematogenous 13 years (12-16)
EEG = electroencephalogram
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CJD, may lead to shorter incubation
periods, and has been associated
with various phenotypes of the
disease (11,38). The proportion of
polymorphism among persons with
sporadic CJD is more similar to the
proportion of polymorphism among
persons with iatrogenic CJD than
to that in the general population
(Table 2), which suggests that sim-
ple stochastic events do not fully
explain sporadic CJD; were that so,
the distribution of homozygosity
would be the same in both healthy
controls and persons with sporadic
cases. The clinical symptoms in
patients with  iatrogenic and with
sporadic CJD have been compared
and are indistinguishable (18).
Is CJD Transmitted by Blood
Transfusions?
Animal Experimentation Data
Human CJD has been reported to be trans-
mitted to mice by injecting blood from human
patients directly into mouse brain (39,40). How-
ever, this evidence has not been widely dupli-
cated by other laboratories, and a comprehensive
review of three decades of research with non-
human primates by the National Institutes of
Health indicated that the blood of humans with
CJD injected either peripherally or centrally into
primates did not transmit CJD (41).
Some evidence indicates that blood of experi-
mentally infected animals contains an infective
agent. PrP infectivity resides predominantly or
exclusively in lymphocytes and monocytes rather
than in granulocytes (42,43); there has been no
evidence of infectivity in erythrocytes, platelets,
or plasma, but low infectivity has not been com-
pletely excluded. Animal studies have demon-
strated that the agent causing scrapie replicates
first in the spleen and other lymphoid tissues but
reaches highest titer in the brain, where it results
in the clinical appearance of disease (44). Hence,
peripheral tissues in contact with blood also
harbor PrP infectivity. Animal transmission data
indicate that human spleen, lymph nodes, serum,
and cord blood are irregularly infective for ani-
mals, although few cord blood samples have been
tested (27). Brown has recently reported trans-
mission of mouse scrapie using fractionated
blood administered by intracerebral inoculation
(P. Brown, Pers. Comm.). Studies of experimental
CJD in guinea pigs and mice have shown that the
infectious agent is present in the brain, viscera,
and blood before clinical disease develops (43,45).
Several factors must be considered in
reviewing animal evidence regarding transmis-
sion of CJD in blood: the level of PrP infectivity of
the study tissue, the species barrier, and the
route of administration. Human CJD can be
readily transmitted to nonhuman primates (low
species barrier) by intracranial injection (high
efficiency of the infective route) of contaminated
brain (high titer of infectivity). Human CJD is not
readily transmitted to dissimilar species (such as
rodents) and is even less readily transmitted
when low-titer tissues (e.g., blood cells) and/or a
low efficiency route of inoculation is used. In ani-
mals, peripheral inoculation of brain tissue trans-
mitted CJD only irregularly, but the incubation
periods were comparable to central administration
(41). Barriers to transmission also include the
difficulties in infecting peripheral cells and cros-
sing the blood brain barrier and possibly the lack
of structural similarity between peripheral
PrPCJD and brain PrPC. Strain variation may also
contribute to the difficulties of transmission to
animals. Deslys et al. suggest that the route of
inoculation may induce strain differentiation,
which then facilitates subsequent transmission
by the same route (46). Others disagree (47). The
evidence from animal studies is inconclusive
regarding transmission of CJD between humans
by transfusion, and study design and laboratory
techniques are controversial.
Table 2. Amino acid phenotypes for codon 129 in patients with iatrogenic
Creutzfeldt-JakobDisease
Homo- Total No.
Tested groups Met/Met Met/Val Val/Val zygous tested
(%) (%) (%) (%)  (n)
Sporadic CJD (38) 78 12 10 88    73
All Iatrogenic 60 11 29 89    63
Cases (27)
  CNS route 80 10 10 98    20
      of infection
  Peripheral route 51 12 37 88    43
     of  infection
Healthy controls (27) 37 51 11 49   261
Healthy controls (38) 48 42 10 58 1397
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Evidence from Studies of Humans
Human Case Series and Case Reports
Case series and case reports provided infor-
mation linking CJD to receipt of dura mater and
human growth hormone. However, no human
cases have yet been causatively linked to blood
transfusion. A transplant recipient developed
CJD (48) after receiving a liver from a donor who
died of a cerebrovascular accident and had no
symptoms of CJD; however, an autopsy was not
performed, and brain tissue was not available for
further investigation. The liver recipient did not
have any of the known PrP gene coding sequences
pathognomonic of familial transmission. The donor
also provided a heart (to a recipient who died
shortly after surgery) and a kidney (to yet ano-
ther recipient; it was removed after 2 months);
the latter recipient remains well. The liver reci-
pient also received transfusions of blood, plasma,
albumin, and anticytomegalovirus immuno-
globulin from other donors. None of the blood
donors is known to have had CJD, but one of the
albumin donors died of a rapidly developing
undiagnosed dementia.
Four Australians have been reported with
CJD following transfusion (49). The patients
had cerebellar signs; however, no other evi-
dence of iatrogenic cause was described (50).
The source of blood transfusions was undocu-
mented. Genetic testing results were not
provided; it is uncertain if cases were of the
familial type, and no other information on
alternative iatrogenic sources was provided.
In Canada, an albumin recipient died of
neuropathologically confirmed CJD after receiving
albumin from a pool containing blood from a
person who died of neuropathologically confirmed
CJD (D.G. Patry, pers. comm.). Eight months
separated the receipt of albumin and development
of symptoms, a much shorter period by a factor of
three than seen in any other putative iatrogenic
case, which makes iatrogenic transmission
unlikely. A complete investigation is under way.
Without an experimental, diagnostic, or
epidemiologic tool that can distinguish sporadic
from iatrogenic disease or link the agent from a
source with a recipient, it is difficult to draw any
conclusions from the case reports described above.
Statistically, a certain number of persons
exposed to pooled blood would be expected to
develop CJD. In addition, bias is introduced into
case reports because of strong suspicion regarding
iatrogenic sources. Verifying the statistical pro-
bability of cases by calculating the expected
number of cases is difficult, if not impossible,
because CJD is rare.
Surveillance
Population surveys or surveillance systems
of the worldwide epidemiology of CJD indicate that
CJD occurs in the population at a rate of 0.05 and
1.5 cases per million per year. After 1979, the rates
are 0.3 to 1.5 cases per million per year (1-8). The
age distribution patterns are consistent and
show that cases in persons under 30 years of age
are extremely rare; cases in persons under 50
years of age are rare; and the peak age of onset is
60 to 70 years. In age-specific data, rates decline
in older age groups (2,6-8,51).
If CJD is transmissible in blood, cases should
occur in young persons, particularly if the incu-
bation period is short. Even if the incubation
period is decades long, one would expect cases in
young persons because of transfusions given to
infants and children. However, CJD is rare in
young persons and remains rare over time.
Alternatively, the rare diagnosis of CJD in
younger age groups may be due to preferences for
neurologic disease diagnoses in these groups.
Recent attention to nv-CJD in 14 persons under
the age of 40 years in the United Kingdom, which
has an intensive active surveillance system, will
certainly affect investigations of unexplained
mental deterioration among younger populations
(22). The British Paediatric Surveillance System
has initiated investigations into undiagnosed
progressive neurologic disease among children
(C. Verity, A. Nicoll and R. Will, pers. comm.),
and Canada will initiate a similar system. In the
United States, the Centers for Disease Control
and Prevention has enhanced surveillance for
CJD in persons under 55 years of age (52).
If CJD is transmitted in blood, the last three
to four decades might show a detectable increase
in cases reflecting the increasing use of blood
transfusions. In fact, surveillance data demon-
strate that CJD rates are increasing in some
countries. Interpretation of this finding is dif-
ficult: most surveillance systems were initiated
in the last two decades; in countries with
intensive surveillance, “catch-up” from previous
underreporting led to initial increases in case
numbers and rates; few countries have sufficiently
intensive surveillance systems to conclude that
there is no risk from blood; and the death159 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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certificates used for surveillance in some coun-
tries are sometimes incomplete, which may intro-
duce a bias toward easily ascertained cases (8,51).
If CJD is transmitted in pooled blood pro-
ducts, clusters would be detected; indeed, sur-
veillance systems have expected such clusters.
However, observation of one or two cases often
leads to more careful search for cases. Most such
clusters have been attributed to familial disease
(1,53). Cluster investigations in surveillance
systems have not systematically searched for
blood-related transmission.
Surveillance systems have found cases of CJD
among persons who have received blood trans-
fusions, but none have been linked to blood trans-
mission. In the United Kingdom, the well-
established surveillance system identified nv-CJD,
despite its rarity, demonstrating the capability
of surveillance to find rare diseases; nv-CJD
was recognized quickly because of the young
age of the patients and the novel neuro-
pathologic findings. However, the absence of
evidence is not evidence of the absence of trans-
mission of CJD through blood, for two reasons:
1) surveillance systems designed to identify
rare diseases need intensive resource allocation
to detect sentinel events and 2) blood-borne
transmission may go unnoticed when examining
population data if unaccompanied unique
epidemiologic features (such as extreme youth
or novel neuropathologic features).
If CJD is transmitted in blood, cases could
increase in industrialized countries, where access
to blood transfusion is greater. The  number of
reported cases is larger; however, cases have
been found in every country in which they have
been sought, although some countries have
limited surveillance capacity. While some coun-
tries have higher rates of CJD, there is no evi-
dence that this is due to transmissible forms of
the disease. Rather, the higher rates are most
likely due to older age distributions in indus-
trialized countries’ populations, surveillance
biases following intensified surveillance for
CJD, and familial clusters.
Finally, in many surveillance systems, the
age distribution pattern for CJD is uniform
(2,7,8,51). The pattern is more consistent with
early exposure to an agent with long incubation
periods, a common population exposure that
peaked long ago and is now declining, or a
heritable disorder that causes shortened life-
span than with a risk which increases with age
(e.g., spontaneous genetic mutation or stochastic
change of the normal prion to the ß-pleated form).
However, CJD may be uniformly underdiagnosed
in older age groups; because of nv-CJD there will
likely be increased attention to differential diag-
noses among elderly persons dying of rapidly
progressing dementing illnesses. We do not
suggest that all sporadic cases are due to external
exposure such as blood, but rather we draw
attention to an important epidemiologic charac-
teristic of CJD that is not consistent with an
entirely stochastic or age-related event.
Case Control Studies
In three countries, case-control studies of
CJD have included questions regarding exposure
to blood: Japan (54), the United Kingdom (55-58),
and the United States (59). In the Japanese
study, only one case-patient and three controls
received blood transfusions. Two of the United
Kingdom studies indicate no difference in expo-
sure to blood between the case-patients and
controls (55,58). A comparison of the frequency of
receipt of blood among persons with CJD and
controls matched for age and sex using data
collected in the United Kingdom CJD surveillance
system between 1980 and 1984 (56) showed no
difference in the history of blood receipt between
those with and without CJD. Although an odds
ratio (OR) is not calculated for the data, our
calculations indicate the OR is 0.78 (95% con-
fidence interval 0.38, 1.58) with a power of only
30% to detect an OR different from one (60).
Davinipour (mid-Atlantic United States) also
found that blood exposure posed no risk, with
an OR for blood transfusion of 0.6 (59). How-
ever, with only 26 cases, the confidence inter-
vals or number of patients exposed was not
mentioned, although the OR is described as
significant. Wientjens et al. analyzed pooled
data for 178 cases and 333 controls from three
case-control studies (Japan, United States,
United Kingdom) and did not find an OR dif-
ferent from one for blood transfusion (61).
Although not using a formal case-control
study, Operskalski et al, compared rates of
human immunodeficiency virus (HIV) dementia
among three HIV-positive groups (persons with
hemophilia, “other blood recipients,” and “blood
donors”) using data from the Transfusion Safety
Study (62). They hypothesized that if CJD was
misdiagnosed as HIV dementia but was the true
cause of dementia, there would be an excess rate160 Emerging Infectious Diseases Vol. 3, No. 2, April–June 1997
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of HIV dementia in persons with hemophilia due
to their high rates of exposure to blood and blood
products (persons with hemophilia were exposed
to the blood or product made from pools of
hundreds of thousands if not millions of dona-
tions). In addition, since the study contained data
from as early as the 1950s, long periods of
observation were available. Rates of HIV demen-
tia in the study populations were compared, and
CJD in pooled plasma derivatives did not pose a
risk. However, it cannot be concluded that rare
diseases such as CJD would be detectable in
increased rates of misdiagnosed HIV dementia or
that diseases with long incubation periods may
have sufficient time to develop in persons with
hemophilia. Any disease with an incubation
period longer than that of HIV would be in
competition with AIDS and hepatitis B or C as a
cause of death, and persons with hemophilia and
HIV infection die young. In addition, the data
included the cause of death of 1,000 HIV-infected
persons but did not provide information on
duration of observation or an estimate of the rate
of disease that would be necessary before even
one additional case would be observed.
The primary weakness found in these pub-
lished case-control studies is the use of the
categories “exposure to blood” or “blood trans-
fusion” as a surrogate for exposure to blood
containing the agent of CJD. If the agent of CJD
is frequently present in blood used for trans-
fusions, the case-control study design is suf-
ficiently robust to detect a risk. However, trans-
mission of CJD through transfusion of blood con-
taminated with the agent of CJD appears to be
rare. Consequently, a negative finding of risk
attributable to blood in these studies may simply
reflect an absence of exposure to the disease. Study
design will have to account not only for a rare
disease, but possibly for a rare exposure as well.
In addition, when hospitalized persons are
used as controls, the design must consider
Berkson’s bias, a selection bias that occurs when
the selection method for controls affects the rate
of exposure to the agent studied (63). The study
design must then show that hospitalized controls
do not have a different rate of potential exposure
to blood transfusion from the general population.
The use of population controls may be more
appropriate for studying blood exposure.
Another weakness in the existing studies was
the use of a reporter, most often a relative, to
collect information about exposure to blood or
blood products. Oral history of blood exposure
tends to underestimate the rate of exposure to
blood. In one Canadian hospital conducting a
retrospective study, approximately 40% of patients
did not know if they had received a blood
transfusion (C. Kennealy, Pers. Comm.). In a
central Ontario hospital, 25% of recipients did
not know if they had received a blood transfusion
(S. King, Pers. Comm.). Given that CJD and
transfusion-transmitted CJD (if it occurs) are
rare, the published case-control studies lack the
power to detect very low ORs.
The 126 hemophilia centers in the United
States have been asked to report deaths of
persons with neurologic symptoms for neurologic
confirmation of cause of death; no CJD cases have
been reported in persons with hemophilia (B.
Evatt and L. Schonberger, Pers. Comm.). The
Canadian Haemophilia Society has requested
assistance from the Health Canada, Laboratory
Centre for Disease Control, to initiate a similar
study in Canada (D. Wong-Reiger, Pers. Comm.).
In Canada, a combined active surveillance sys-
tem and case control study will begin in 1997 to
identify the risk for CJD as a result of transfusion
with blood from a person with CJD. Many of the
methodologic problems in other studies have
been addressed in the design of this study.
Cohort Studies
The investigation of a patient with CJD who
donated 35 units of blood in 20 years identified 27
persons who definitely received his blood and
eight who probably received blood; for 20 units,
the recipients could not be identified (64). Eigh-
teen (33%) of the identified recipients had died.
None of the recipients had exhibited neurologic
disease, although some were observed only briefly;
only eight were observed for longer than 5 years.
In the United States, the American
Association of Blood Banks has initiated a long-
term cohort investigation. By linking the names
of persons who received blood from CJD patients
with the national death records, the cause of
death for each person will be determined. Of the
147 recipients identified, 80 have died; for 65, the
cause of death is known but no cases of CJD have
been found (M. Sullivan, Pers. Comm.).
Cohort studies are unlikely to accumulate
enough cases of exposure to allow a reasonably
precise estimate of risk. However, if pooled
product confers uniform risk to each recipient,
data from a large number of exposed recipients161 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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can be collected. The cohort studies under way
may be able to identify higher than expected
rates of disease, thus indicating transmission
through blood transfusion without quantifying
the rate of transmission.
Conclusions
Many health professionals are concerned
that CJD may be transmissible through blood. As
noted by Brown, “iatrogenic disease from this
source would dwarf in importance all other sources
by virtue of the sheer number of people who
theoretically have been or could be at risk” (27).
Animal studies indicate that the infective
agent of CJD is present in blood but in low titer,
and sufficient evidence of animal transmission
suggests that the disease has the potential to be
transmitted through blood (65). However, human
epidemiologic evidence only indicates that if blood
transmission occurs, it is likely rare. Some
researchers suspect that the agent of CJD is
ubiquitous, therefore, we are commonly exposed
to it; perhaps, another, as yet unidentified factor,
“turns on” the disease. If so, is there any part of
the human population that is not exposed? Most
people are exposed to some components of blood
products through vaccines. Some people may be
protected by strain variation through exposure to
nonvirulent forms, so only subgroups are suscep-
tible to a virulent form (66). Polymorphism at codon
129 may restrict susceptibility to a small portion
of the population, or most transfusions may not
contain a dose large enough to cause infection.
Can experimental studies answer these ques-
tions? Sufficiently large numbers of study animals
could overcome problems such as the species
barrier and low transmission rates due to a low
dose or peripheral route of inoculation. The
studies would require strict adherence to proper
laboratory technique and replication in at least
one other laboratory. Unanswered questions
include the following: Can the transmissible
spongiform encephalopathies of animals be trans-
mitted, by transfusion, within the species when
spiked blood is used? Within species from
“naturally infected” blood? From humans to
animals with spiked blood? From humans to
animals with “naturally infected” blood? Does
transmission by blood become more efficient after
passage? Can human blood cells carry the agent?
What are the routes for infection of the brain if
infection is peripheral?
Can epidemiologic methods detect blood
transmission of CJD if it is rare? Epidemiologic
tools such as outbreak investigations, case-
control studies, and cohort studies are limited in
their ability to detect rare events. In addition,
during the long incubation period, patients often
move away from the location where they received
the transfusion; forget their exposure; and essen-
tially lose their membership in a recognizable
cohort. The absence of a test for exposure, such as
an antibody test or gene sequencing of an agent
as used in investigating HIV-related out-
breaks, makes the investigation of iatrogenic
CJD extremely difficult, hence the importance of
vigilance, in the form of case reports from alert
and informed clinicians, followed by critical field
investigation. Surveillance systems provide the
core resources for identifying and investigating
unique or unexplained events. Followup case-
control studies allow the observation and
recording of the actual chain of exposure to blood.
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